CYCLOPHARM LIMITED — Board/Management Information 2021

Nov 30, 2021

1 December 2021

The Manager Company Announcements Office Australian Securities Exchange Limited 20 Bridge Street Sydney NSW 2000

==> picture [42 x 55] intentionally omitted <==

cyclo pharm

cyclo medica techne gas ultra lute Cyclopharm Ltd ABN 74 116 931 250 Unit 4, 1 The Crescent Kingsgrove NSW 2208 Australia T 61 2 9541 0411 F 61 2 9543 0960 www.cyclopharm.com.au

DIRECTOR CESSATION – TOM MCDONALD

The Board of Cyclopharm Limited (ASX:CYC) wishes to advise that Mr Tom McDonald has retired as Director of the Company for personal health reasons. Mr McDonald’s retirement takes immediate effect.

The Board acknowledges and thanks Mr McDonald for his significant and valuable contribution as a director of the Company since joining the Board in 2017.

Cyclopharm Chairman, Mr David Heaney said, “The Board and management of Cyclopharm have greatly valued the depth of experience, wisdom and considered guidance Tom provided during his tenure, and we thank him for his service and ongoing friendship.”

The Company intends to commence a search process for Mr McDonald’s replacement on the Board and will advise shareholders of the outcome of this process in due course.

ENDS

This ASX announcement was approved and authorised for release by the Board of Cyclopharm Limited.

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company’s mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700[o] C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

Page 1 of 1